Clinical trials: sponsored by UNC Lineberger Comprehensive Cancer Center
Physical Activity, Neoplasms
Promoting Physical Activity in Young Adult Cancer Survivors Using mHealth and Adaptive Tailored Feedback Strategies
To date, few interventions have been designed specifically to promote physical activity in young adult cancer survivors, nor used novel technologies for delivery; none have been successful in promoting long-term adherence to PA.
- Conditions
- Physical Activity, Neoplasms, Neoplasms by Site, Cancer
- Trial name
- IMPACT (NCT03569605)
- Testing
- Self-help, Intervention
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Sarcoma
PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas
Purpose: To assess the utility of PET/MR in assessing response to neoadjuvant radiation therapy in the treatment of high grade sarcomas.
- Trial name
- NCT03076333
- Testing
- PET/MR
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Rectal Carcinoma
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.
- Trial name
- NCT01751516
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
Purpose: The purpose of this trial is to investigate whether a microfluidics assay can detect trace amounts of residual leukemia and predict relapse in acute myeloid leukemia (AML) patients in remission who have undergone…
- Trial name
- NCT03488862
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Small Cell Lung Cancer
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
- Trial name
- NCT01573702
- Testing
- Stereotactic Radiosurgery, Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Renal Cell Carcinoma
Imaging Correlates of Renal Cell Carcinoma Biological Features
This pilot study is designed to evaluate imaging parameters indicative of underlying tumor biology. Patients with large renal masses (>3 cm, or at the discretion of the investigator) who are planning to undergo nephrectomy will…
- Trial name
- NCT01665703
- Testing
- FDG PET/MR
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer Metastatic
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously…
- Trial name
- NCT01298570
- Testing
- Regorafenib (BAY 73-4506), FOLFIRI
- Where
- 24 sites in United States, Ireland
- Volunteers
- 181 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Kaposi Sarcoma, HIV
Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
The purpose of this study is to identify important associations between complete and comprehensive clinical, laboratory, and genomic data derived from patients and tumor specimens, with prospectively recorded clinical outcomes.
- Trial name
- NCT03160183
- Where
- 2 sites in Malawi
- Volunteers
- 157 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Neoplasm of Lung, Decision Support Techniques
Effect of Incidental Findings Information on Lung Cancer Screening Intent
This online randomized controlled trial seeks to determine if inclusion of incidental findings information in a lung cancer screening decision aid affects screening intent among screening-eligible individuals.
- Conditions
- Neoplasm of Lung, Decision Support Techniques, Mass Screening
- Trial name
- NCT04432753
- Testing
- Lung Cancer Screening Decision Aid with Incidental Findings Information, Lung Cancer Screening Decision Aid without Incidental Findings Information
- Where
- United States
- Volunteers
- 419 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cigarette Smoking Behavior
Enhancing Source Credibility in Tobacco Regulatory Communications
This study will assess the impact of cigarette constituent messages with and without FDA source and quit information in a randomized controlled trial.
- Trial name
- NCT03339206
- Testing
- Constituent message with FDA and quitline, Constituent message without FDA and quitline, Littering message (Control)
- Where
- United States
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Cancer
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
- Trial name
- NCT01412229
- Testing
- Cetuximab, Nab-paclitaxel, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Stage III Melanoma, Stage IV Melanoma
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
This phase II study in 20 patients with BRAFV600E mutant, unresectable stage III/IV melanoma is designed to explore the mechanisms by which tumors acquire resistance to the combination of a BRAF inhibitor (dabrafenib) and MEK…
- Conditions
- Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
- Trial name
- NCT01726738
- Testing
- BRAF inhibitor dabrafenib and MEK inhibitor trametinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer, Breast Neoplasms
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
The purpose of this research study is to find the lowest dose of the cancer drug parsaclisib that has an effect on the type of breast cancer a participant has. Researchers are looking at how Parsaclisib affects the immune system.
- Conditions
- Breast Cancer, Breast Neoplasms, Triple Negative Breast Cancer, HER2-positive Breast Cancer
- Trial name
- LCCC1820 (NCT04142554)
- Testing
- Parsaclisib
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Rectal Cancer
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
This trial will enroll patients with locally advanced rectal cancer (resectable and non-resectable).The phase Ib dose escalation portion of trial is designed to determine the maximum tolerated dose (MTD) of CRLX101 when combined…
- Trial name
- NCT02010567
- Testing
- CRLX101, Capecitabine, Radiotherapy
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Small Cell Lung Cancer (NSCLC)
Single Arm on the Tolerability of Weekly Nab-paclitaxel
The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)
- Trial name
- NCT01702844
- Testing
- Nab-Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using A Couple-focused Web-based Tailored Symptom Self-management Program
The purpose of this research study is to examine the feasibility of the enhanced survivorship care plans (ESCPs, regular SCPs with the a web-based couple-focused symptom self-management project (PERC) or National Cancer Institute…
- Trial name
- SCP (NCT04350788)
- Testing
- Survivorship Care Plan, Enhanced Survivorship Care Plan
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Neoplasms
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Kinases are a group of proteins that are important in how cancer cells grow. HER2 is a kind of kinase. This study looks at a new approach to identifying kinases, which may help target therapy more precisely.
- Trial name
- NCT01875666
- Testing
- Trastuzumab, pertuzumab, lapatinib
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
Research into treatments for breast cancer relies more and more on an understanding of how the cells of tumor tissue act when they are exposed to a new or different drug.
- Trial name
- NCT01467310
- Testing
- GSK1120212
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
This is a non-randomized, open-label phase II trial of 38 patients with recurrent or metastatic SCCHN. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 with good organ function and will be…
- Trial name
- NCT02124707
- Testing
- Cetuximab, Paclitaxel, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrium Cancer, Sentinel Lymph Node
Multimedia Aid Gynecologic Counseling and Consent
This is an interventional trial to introduce two short animated videos into preoperative counseling/consent and to compare patient comprehension and satisfaction with a multimedia approach compared to standard of care currently.
- Conditions
- Endometrium Cancer, Sentinel Lymph Node, Perioperative/Postoperative Complications
- Trial name
- NCT03899441
- Testing
- Video
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center